Ocumension Therapeutics (HKEX:1477)

Executive Summary

Ocumension Therapeutics is a China-based biopharmaceutical company specializing in innovative ophthalmic therapies with advanced drug delivery technologies. Founded in 2020 and publicly traded on HKEX (ticker: 1477), the company has raised over $300 million to develop treatments for dry eye disease, glaucoma, and retinal disorders. Its pipeline leverages novel formulations and delivery systems to enhance efficacy and patient compliance, positioning it to address significant unmet needs in ophthalmology. The company is currently in Phase 2 clinical development for its lead candidates, with a focus on progressing toward late-stage trials and potential regulatory submissions in China.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Top-Line Data for Dry Eye Disease Candidate35% success
• Q1 2027Phase 3 Initiation for Glaucoma Candidate80% success
• Q2 2027Regulatory Submission in China for Retinal Disorder Therapy25% success